title: The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women.
abstract: The recent Women's Health Initiative study report evaluated the long-term benefits and risks of hormone replacement therapy among healthy postmenopausal women. The report showed that the risk-benefit profile of continuous combined hormone replacement therapy was not consistent with the primary prevention of coronary heart disease. The Women's Health Initiative study of continuous combined hormone replacement therapy is a landmark study and the results provide valuable information for patients and clinicians. However, the most common indication for hormone replacement therapy is menopausal symptoms, for which it is effective, not prevention of disease, and the most common use is for less than three years. Nevertheless, even short-term use has small effects on some outcomes. This statement discusses how the findings of the Women's Health Initiative study can be applied to reach appropriate clinical decisions.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Blake
authors.forename: John A
authors.initials: JA
authors.lastname: Collins
authors.forename: Robert L
authors.initials: RL
authors.lastname: Reid
authors.forename: Donna M
authors.initials: DM
authors.lastname: Fedorkow
authors.forename: André B
authors.initials: AB
authors.lastname: Lalonde
authors.forename: Jan
authors.initials: J
authors.lastname: Christilaw
authors.forename: Michel
authors.initials: M
authors.lastname: Fortier
authors.forename: Claude
authors.initials: C
authors.lastname: Fortin
authors.forename: Elaine E
authors.initials: EE
authors.lastname: Jolly
authors.forename: André
authors.initials: A
authors.lastname: Lemay
authors.forename: Terry
authors.initials: T
authors.lastname: O'Grady
authors.forename: Thirza E
authors.initials: TE
authors.lastname: Smith
authors.forename: Janet
authors.initials: J
authors.lastname: Cooper
authors.forename: John M
authors.initials: JM
authors.lastname: Maxted
authors.forename: Kathleen
authors.initials: K
authors.lastname: O'Grady
authors.forename: Michele A
authors.initials: MA
authors.lastname: Turek
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D004338:Drug Combinations; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods / Q000592:standards*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D019317:Evidence-Based Medicine / Q000592:standards; D005260:Female; D006801:Humans; D007258:Informed Consent; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010353:Patient Education as Topic; D018579:Patient Selection; D017698:Postmenopause / Q000187:drug effects*; D012306:Risk; D012307:Risk Factors; D016387:Women's Health
chemical_list: D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); C466383:Prempro; D017258:Medroxyprogesterone Acetate